DAFNA Capital Management »

Neurogene shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Neurogene (NGNE) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Neurogene

Tip: Access up to 7 years of quarterly data

All positions including Neurogene held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Neurogene by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $326k 7.8k 41.96
2024-06-30 $400k 11k 36.39

More positions owned by DAFNA Capital Management

Spdr S&p Biotech Etf Etf (XBI)
Stereotaxis Com New (STXS)
Revolution Medicines (RVMD)
Cytokinetics Com New (CYTK)
Merus N V (MRUS)
AtriCure (ATRC)
Ideaya Biosciences (IDYA)
Ishares Nasdaq Biotech Indx Etf (IBB)
Ascendis Pharma A/s Sponsored Adr (ASND)
Axogen (AXGN)
Blueprint Medicines (BPMC)
Xenon Pharmaceuticals (XENE)
Day One Biopharmaceuticals I (DAWN)
Syndax Pharmaceuticals (SNDX)
Biohaven (BHVN)

View all positions for DAFNA Capital Management

Top funds holding Neurogene

BlackRock
BlackRock
EcoR1 Capital
Samsara BioCapital
Dr. Jeffrey R. Jay, M.D.
Redmile Group
Henderson Group
Vanguard Group
Casdin Capital
Baker Bros. Advisors
Avidity Partners Management
Arrowpoint Asset Management
Morgan Stanley
Deutsche Bank Aktiengesellschaft
Geode Capital Management

View all funds holding Neurogene